FDA drug data now shared with patent examiners—with weak confidentiality guardrails
H.R. 4570 — Interagency Patent Coordination and Improvement Act of 2025 · Filed by Joe Neguse (D-CO) · Introduced Jul 21, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a formal task force between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) to share information about drug patents and approvals. Patent examiners will gain access to FDA data on drug approvals, labeling changes, and prior art to make better patenting decisions, while the FDA will receive help organizing patent listings. The bill requires a 4-year report on how useful this coordination is and whether other agencies should join.
Why we flagged it
The bill's core function is establishing a formal information-sharing mechanism between two federal agencies to improve patent examination quality. It is neither a deregulation nor a subsidy, but rather a procedural coordination measure with both transparency and confidentiality safeguards.
What the text implies
- Patent examiners will gain access to confidential drug-sponsor information (product applications, approval communications) not subject to public disclosure. While protocols are required, the 30-day notice period may be insufficient for sponsors to object, and 'inadvertent disclosure' remedies are vague.
- The bill does not specify funding for the task force, leaving appropriations uncertain. If underfunded, the coordination may be nominal, or if well-funded, it could shift resources away from other USPTO functions.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies (improved patent examination may strengthen patent protection for drugs); biotechnology firms (similar benefit from better prior-art assessment)